Adimmune Receives TWD 300M License Fee for COVID-19 Candidate Vaccine

Adimmune Corporation (TPE: 4142) announced on 23rd that it has signed a Licensing Agreement for exclusive distribution and sales of AdimrSC-2f, Adimmune’s COVID-19 candidate vaccine, with Enimmune Biotech Pte. Ltd., a joint venture between Aios Biotech Pte. Ltd. and Enimmune Corp. in Southeast Asia. 

AdimrSC-2f had its Phase 1 human clinical trial done in Taiwan, and received the Indonesian authority’s (BPOM) approval for Phase I/II in September. Further clinical trials are being planned at various research centers in multiple countries.

Adimmune is optimistic about the market prospects of Southeast Asia and Muslim countries, and has plans to build manufacturing facilities in Indonesia. The company’s vaccines have already received halal certifications for greater acceptance in Muslim countries.

The agreement is to license the technical achievements of AdimrSC-2f and grant the exclusive use and distribution rights in the territory of Southeast Asia to Enimmune Biotech. In addition to COVID-19, other vaccines including EV-71 vaccine, tetanus toxoid, and Enimmune’s COVID-19 rapid test kit will be distributed in the Southeast Asian markets through Enimmune Biotech as well. The licensed territory includes Vietnam, Laos, Cambodia, Thailand, Myanmar, Malaysia, Brunei, Singapore, Indonesia, East Timor, and the Philippines. 

The Licensing Agreement stipulates milestone payments totaling TWD 300 million, plus running royalties following market approval of the COVID-19 vaccine.

About Enimmune Biotech Pte. Ltd.:
Founded in Singapore in November 2021, with a capital of USD 10 million, Enimmune Biotech Pte. Ltd. is a joint venture between Aios Biotech Pte. Ltd. and Enimmune Corp. (TPE: 6564). The company is to provide comprehensive services for vaccines and test kits products from clinical research to approval and sales in Southeast Asia.

About Aios Biotech Pte. Ltd.:
Aios Biotech Pte. Ltd. is a subsidiary of Innovalues Pte. Ltd., an affiliate of Northstar Group in Singapore. Innovalues has a capital of USD 350 million. In 2020, renamed to Aios Biotech, the company has repositioned itself to strategic planning and investment service for biopharmaceutical products. It has investments in a number of medical centers in Singapore, Indonesia and Malaysia, and engages in other pharmaceutical services.

About Enimmune Corp.:
Enimmune Corp., with a capital of TWD600 million, is a subsidiary of Adimmune Corporation. The business scope of Enimmune comprises new drug clinical trials and development of distribution and sales channels for biotech drugs. The current product line consists of quadrivalent influenza vaccine, tetanus toxoid, and antigen rapid test kits, while products under development include EV-71 vaccine, Japanese encephalitis, and pneumococcal vaccine.